AlphaQuest LLC Acquires 43,575 Shares of Inogen, Inc $INGN

Key Points

• AlphaQuest LLC significantly increased its stake in Inogen, Inc by 924.4% in the first quarter, holding approximately 0.18% of the company with a total of 48,289 shares valued at $344,000.
• Inogen reported earnings of ($0.15) per share for the last quarter, surpassing analysts' expectations, and generated revenue of $92.28 million, exceeding the consensus estimate of $90.40 million.
• The stock has an average rating of "Moderate Buy" with a consensus price target of $11.00, despite different analysts setting varied target prices in recent reports.

AlphaQuest LLC grew its holdings in shares of Inogen, Inc (NASDAQ:INGN - Free Report) by 924.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,289 shares of the medical technology company's stock after purchasing an additional 43,575 shares during the period. AlphaQuest LLC owned approximately 0.18% of Inogen worth $344,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Hsbc Holdings PLC boosted its position in shares of Inogen by 111.9% during the 1st quarter. Hsbc Holdings PLC now owns 31,413 shares of the medical technology company's stock valued at $210,000 after purchasing an additional 16,586 shares in the last quarter. Algert Global LLC bought a new position in shares of Inogen during the 1st quarter valued at about $89,000. American Century Companies Inc. boosted its position in shares of Inogen by 6.4% during the 1st quarter. American Century Companies Inc. now owns 58,380 shares of the medical technology company's stock valued at $416,000 after purchasing an additional 3,524 shares in the last quarter. Sei Investments Co. boosted its position in shares of Inogen by 141.5% during the 1st quarter. Sei Investments Co. now owns 40,285 shares of the medical technology company's stock valued at $287,000 after purchasing an additional 23,601 shares in the last quarter. Finally, Nuveen LLC bought a new position in shares of Inogen during the 1st quarter valued at about $1,097,000. Institutional investors own 89.94% of the company's stock.

Inogen Price Performance

Shares of NASDAQ INGN traded up $0.03 during mid-day trading on Friday, reaching $7.99. The company had a trading volume of 167,360 shares, compared to its average volume of 270,789. The stock has a fifty day moving average of $7.04 and a two-hundred day moving average of $7.19. Inogen, Inc has a 12-month low of $5.70 and a 12-month high of $13.22.

Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical technology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.07. The business had revenue of $92.28 million during the quarter, compared to analyst estimates of $90.40 million. Inogen had a negative net margin of 7.58% and a negative return on equity of 13.77%. Inogen has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts predict that Inogen, Inc will post -1.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

INGN has been the subject of a number of analyst reports. B. Riley initiated coverage on shares of Inogen in a research note on Monday, June 16th. They set a "buy" rating and a $14.00 price objective for the company. Stifel Nicolaus reduced their price objective on shares of Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a research note on Thursday, May 8th. Finally, Needham & Company LLC raised shares of Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price objective for the company in a research note on Thursday, May 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $11.00.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.